NewAmsterdam Pharma Company NV
NAMS37.425USD
+0.425+1.15%
取引時間 （ET）15分遅れの株価
4.21B時価総額
損失額直近12ヶ月PER
詳細情報 NewAmsterdam Pharma Company NV 企業名
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NVの企業情報
企業コードNAMS
会社名NewAmsterdam Pharma Company NV
上場日Nov 23, 2022
最高経営責任者「CEO」Dr. Michael Harvey Davidson, M.D.
従業員数68
証券種類Ordinary Share
決算期末Nov 23
本社所在地Gooimeer 2-35
都市NAARDEN
証券取引所NASDAQ Global Market Consolidated
国Netherlands
郵便番号1411 DC
電話番号31352062971
ウェブサイトhttps://ir.newamsterdampharma.com/
企業コードNAMS
上場日Nov 23, 2022
最高経営責任者「CEO」Dr. Michael Harvey Davidson, M.D.
NewAmsterdam Pharma Company NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Douglas Kling
Mr. Douglas Kling
Chief Operating Officer
Chief Operating Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
6.96K
--
Mr. Wouter Joustra
Mr. Wouter Joustra
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Ms. Louise Kooij
Ms. Louise Kooij
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Adele M. Gulfo
Ms. Adele M. Gulfo
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: 16 hours ago
更新時刻: 16 hours ago
株主統計
種類
株主統計
株主統計
比率
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
他の
51.00%
株主統計
株主統計
比率
Frazier Life Sciences Management, L.P.
14.76%
Bain Capital Life Sciences Investors, LLC
9.52%
RA Capital Management, LP
9.00%
Forbion Capital Partners
8.27%
Capital World Investors
7.45%
他の
51.00%
種類
株主統計
比率
Investment Advisor
29.22%
Investment Advisor/Hedge Fund
24.29%
Venture Capital
20.51%
Hedge Fund
15.00%
Private Equity
14.76%
Research Firm
1.68%
Family Office
0.74%
Sovereign Wealth Fund
0.44%
Individual Investor
0.44%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
280
119.62M
106.21%
+3.10M
2025Q2
263
127.89M
114.87%
+4.67M
2025Q1
255
126.71M
112.87%
+7.17M
2024Q4
216
108.34M
98.72%
+13.96M
2024Q3
194
82.73M
88.90%
-12.05M
2024Q2
184
81.92M
90.19%
-12.22M
2024Q1
155
81.92M
90.50%
-4.21M
2023Q4
117
72.34M
86.57%
-9.73M
2023Q3
116
71.44M
85.50%
-13.42M
2023Q2
109
71.10M
86.48%
+7.09M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Frazier Life Sciences Management, L.P.
16.63M
14.76%
+18.71K
+0.11%
Aug 18, 2025
Bain Capital Life Sciences Investors, LLC
10.72M
9.52%
--
--
Jun 30, 2025
RA Capital Management, LP
10.14M
9%
--
--
Jun 30, 2025
Forbion Capital Partners
9.32M
8.27%
-1.26M
-11.93%
Sep 26, 2025
Capital World Investors
8.39M
7.45%
+1.59M
+23.37%
Jun 30, 2025
Viking Global Investors LP
6.98M
6.2%
--
--
Jun 30, 2025
Deerfield Management Company, L.P.
5.12M
4.54%
+1.01M
+24.66%
Jun 30, 2025
Jennison Associates LLC
2.95M
2.62%
-1.02M
-25.79%
Jun 30, 2025
Wellington Management Company, LLP
3.32M
2.95%
-218.98K
-6.18%
Jun 30, 2025
Adage Capital Management, L.P.
3.01M
2.68%
+1.06M
+54.46%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Sun, Nov 2
更新時刻: Sun, Nov 2
銘柄名
比率
ALPS Medical Breakthroughs ETF
1.94%
Global X Guru Index ETF
1.39%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
First Trust NASDAQ Pharmaceuticals ETF
0.59%
Harbor Health Care ETF
0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
0.41%
ProShares Ultra Nasdaq Biotechnology
0.33%
Invesco Nasdaq Biotechnology ETF
0.32%
iShares Biotechnology ETF
0.2%
First Trust IPOX Europe Equity Opportunities ETF
0.15%
詳細を見る
ALPS Medical Breakthroughs ETF
比率1.94%
Global X Guru Index ETF
比率1.39%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.98%
First Trust NASDAQ Pharmaceuticals ETF
比率0.59%
Harbor Health Care ETF
比率0.55%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.41%
ProShares Ultra Nasdaq Biotechnology
比率0.33%
Invesco Nasdaq Biotechnology ETF
比率0.32%
iShares Biotechnology ETF
比率0.2%
First Trust IPOX Europe Equity Opportunities ETF
比率0.15%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
